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http://www.molecular-cancer.com/content/13/1/246RESEARCH Open AccessCopy-neutral loss of heterozygosity and
chromosome gains and losses are frequent in
gastrointestinal stromal tumors
Nelson Lourenço1,10†, Zofia Hélias-Rodzewicz1,2†, Jean-Baptiste Bachet1,3, Sabrina Brahimi-Adouane1,
Fabrice Jardin4, Jeanne Tran van Nhieu5, Frédérique Peschaud1,6, Emmanuel Martin7, Alain Beauchet1,8,
Frédéric Chibon9 and Jean-François Emile1,2*Abstract
Background: A KIT gain of function mutation is present in 70% of gastrointestinal stromal tumors (GISTs) and the
wild-type (WT) allele is deleted in 5 to 15% of these cases. The WT KIT is probably deleted during GIST progression.
We aimed to identify the mechanism of WT KIT loss and to determine whether other genes are involved or affected.
Methods: Whole-genome SNP array analyses were performed in 22 GISTs with KIT exon 11 mutations, including 11
with WT loss, to investigate the mechanisms of WT allele deletion. CGH arrays and FISH were performed in some cases.
Common genetic events were identified by SNP data analysis. The 9p21.3 locus was studied by multiplex quantification
of genomic DNA.
Results: Chromosome instability involving the whole chromosome/chromosome arm (whole C/CA) was detected in
21/22 cases. The GISTs segregated in two groups based on their chromosome number: polyGISTs had numerous
whole C/CA gains (mean 23, range [9 to 43]/3.11 [1 to 5]), whereas biGISTs had fewer aberrations. Whole C/CA losses
were also frequent and found in both groups. There were numerous copy-neutral losses of heterozygosity (cnLOH) of
whole C/CA in both polyGIST (7/9) and biGIST (9/13) groups. cnLOH were frequent on 4q, 11p, 11q, 1p, 2q, 3p and 10,
and never involved 12p, 12q, 20p, 20q or 19q. Other genetic alterations included segmental chromosome abnormalities,
complete bi-allelic deletions (homozygous deletions) and, more rarely, amplifications. Nine of 11 GISTs with homozygous
KIT exon 11 mutations had cnLOH of chromosome 4.
Conclusion: The cnLOH of whole C/CA is a frequent genetic alteration in GISTs and is closely associated with
homozygous mutations of KIT and WT allele deletion.
Keywords: cnLOH, WT KIT allele loss, GISTBackground
About 20 to 30% of extra-osseous sarcomas are gastro-
intestinal stromal tumors [1] which are the most fre-
quent mesenchymal tumors of the digestive tract. Before
1998, their diagnosis was difficult and they were fre-
quently mistaken for muscular or nervous tumors. KIT
[2] and PDGFRA [3] are main driver genes of GISTs. In-
deed, gain of function mutations of these genes are* Correspondence: jean-francois.emile@uvsq.fr
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unless otherwise stated.present in 85% of GISTs [4,5] and KIT inhibitors in-
crease survival of patients with metastatic or localized
GISTs [6,7]. The KIT inhibitor imatinib mesylate is more
effective in patients with mutations in exon 11 of KIT
than in those with KIT exon 9 mutations [8]. The KIT
gene maps on chromosome 4q12 and encodes the pro-
tein KIT, a tyrosine kinase receptor, the activation of
which leads to cell proliferation, differentiation, migra-
tion or increased survival [9]. KIT mutations are early
events in GIST oncogenesis [10], and patients with ger-
minal mutation of KIT have a high incidence of GISTs
[11]. Cytogenetic studies of GISTs with karyotyping,ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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http://www.molecular-cancer.com/content/13/1/246fluorescence in situ hybridization (FISH) and/or comparative
genomic hybridization (CGH) arrays have shown that
many of these tumors have gains or losses in chromosomes
5 and/or 8, and losses in 1p, 14q, 15q and 22q [12-21].
The most frequent mutations of KIT map in exon 11.
In most GISTs, both mutated and wild-type transcripts
are present [22]. However, 5 to 15% of GISTs have loss
of the KIT WT allele from genomic tumor DNA [23].
Expression of mutant KIT in the presence of WT KIT
in vitro has particular cellular effects, different to those
associated with the expression of the mutant alone [24,25].
Patients with loss of WT KIT have a worse prognosis than
those with GISTs containing both WT and mutant alleles
of KIT [23,26].
We used high density whole-genome single-nucleotide
polymorphism (SNP) arrays to study the mechanism of
the WT allele loss in GISTs with KIT exon 11 mutations
and analyze chromosome abnormalities in GISTs.Figure 1 Example of ploidy analysis by FISH with one GIST (#1C2). A)
copy number alteration (bottom plot) are presented. The results of visual g
the upper plot for each chromosome. B) (Right) representative images of F
upper image, the arrow indicates a cell with two chromosomes 4q and five
with four chromosomes 18 and three chromosome 4 centromeric signals.Results
Polyploidy validation by FISH
Chromosome number aberrations revealed by at least
one bioinformatics method (from SNP and CGH array
data) and detailed visual analysis of SNP genetic data
(both copy number alterations (CNA) and allele disequi-
librium (AD)) in BeadStudio software were concordant
for 19 tumors. In three cases (#1C2, #15C2 and #20 s2),
the results of bioinformatics analysis suggested diploid
tumors; however, the visual investigation of CNA and
AD data indicated ploidy higher than two (Figure 1A).
The different ploidy levels were verified by FISH on the
imprints of GIST cell nuclei with at least two different
chromosome probes and confirmed the results of de-
tailed visual analysis of SNP genomic data (Figure 1B).
For cases #1C2 and #20 s2, chromosomes 4q, 7q, 17q,
18 and 22q were tested. Most #20 s2 cells analyzed were
polysomic for chromosomes 4q (mean chromosome number(Left) for chromosomes 4, 7 and 18, allele frequencies (upper plot) and
enotyping of both parental alleles are indicated as “A” and “B” within
ISH analysis of the same tumor for the same chromosomes. On the
chromosomes 7q. On the lower image, the arrow indicates a cell
White bar =10 μm.
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http://www.molecular-cancer.com/content/13/1/2463.2, range [2 to 4]), 7q (mean 3.2, range [1 to 4]), 17q (mean
3.2, range [1 to 4]) and 18 (mean 3.1, range [2 to 4]) (the ex-
pected chromosome number was four copies for all these
chromosomes). All cells analyzed for chromosome 22q had
two copies; however, SNP data suggested only one copy of
this chromosome. In #1C2 samples, most nuclei analyzed
for chromosomes 7q, 17q and 18 were polysomic: the mean
chromosomes number/expected chromosome number was
4.4, range [3 to 8]/6 (BRAF 7q34), 3.4, range [1 to 6]/3 and
3.6, range [2 to 4]/4, respectively. In most cells, two copies of
chromosomes 4q (mean chromosome number 2.2, range
[1 to 3]) and 22q (mean 2.4, range [1 to 4]) were ob-
served as expected from the SNP analysis. For tumor
sample #15C2, FISH signals were only interpretable for
chromosomes 17q and 22q. Most of the nuclei dis-
played polysomy of chromosome 22q (mean 2.5, range
[1 to 4]) but almost all cells were only diploid for
chromosome 17q (mean 2, range [1 to 3]); four copies
of both chromosomes were expected.
Chromosome alterations
Numerous chromosome aberrations were observed, and
most were either quantitative or qualitative. Whole gen-
omic views of the chromosome copy number alterations
and allele disequilibrium are shown in Figure 2. Quanti-
tative abnormalities included either gains (1 copy or
more) or losses (1 copy or more) of whole chromosomes
(C), chromosome arms (CA) and/or chromosome seg-
ments (CS) (Figure 2, Table 1, Additional file 1: Figure S1,
Additional file 2: Table S1). GISTs were classified into two
groups according to chromosome number: polyploid
GISTs called polyGISTs with numerous gains and few
losses of whole C (n = 9, mean whole C gains 23, range
[9 to 43] and mean whole C losses 0.44, range [0 to 3])
and diploid tumors called biGISTs with few gains of
whole C and few losses of whole C or CA (n = 13,
mean whole C gains 0.07, range [0 to 1], mean whole
C losses 2.33, range [0 to 6] and mean CA losses 1.46,
range [0 to 5]) (Figure 2). Tumors were classified as
polyploid if at least five different whole chromosomes
were gained. The biGIST group contained tumors with
near diploid chromosomes sets.
Gains of whole C and CA were detected in 10/22 (45%)
and 16/22 GISTs (73%), respectively. In biGISTs, the mean
gains were 0.07 (range [0 to 1]) and 0.85 (range [0 to 4])
for whole C and CA, respectively, while in polyGISTs the
mean gains were 23 (range [9 to 43]) and 3.11 (range
[1 to 5]) for whole C and CA, respectively. Among the
13 biGISTs, only one (8%) had a whole C gain and 7
(54%) had an increased CA number (Figure 2, Table 1,
Additional file 2: Table S1). By contrast, all polyGISTs
had gained additional whole C or CA. Every type of
gain was present in at least two patients. The most fre-
quently gained C and CA (observed in at least 35% ofGISTs) were: 1q, 2, 4p, 5, 5p, 7, 8, 12, 16, 17q, 18, 19p
and 20. In additional to whole C/CA gains, CS gains were
detected in all polyGISTs but in only 4/13 biGISTs (31%)
(Figure 2, Table 1, Additional file 2: Table S1) (biGISTs
mean CS gains 0.77, range [0 to 4]; polyGISTs mean CS
gains 10, range [0 to 35], P < 0.05). Most of the segmental
copy number abnormalities were found in chromosomes
involved in whole chromosome or chromosomal arm im-
balances, and 31% of them were telomeric.
Losses, defined as the presence of only one copy of a
whole C or a CA, were detected in 14/22 (63%) and 10/22
(45%) of GISTs, respectively (Figure 2, Table 1, Additional
file 2: Table S1). They were more frequent in biGISTs than
in polyGISTs (biGISTs mean whole C losses 2.23, range [0
to 6] and mean CA losses 1.46, range [0 to 5]; polyGISTs
mean whole C losses 0.44, range [0 to 3] and mean CA
losses 0 [0], P < 0.05). The C and CA most frequently
involved (deleted in more than 20% of GISTs) were: 14
(n = 50%), 22 (n = 41%), 1p (n = 36%) and 15 (n = 27%).
Segmental copy number losses were mainly found in
the chromosomes involved in whole C or CA abnor-
malities: they were frequent in biGISTs (9/13), but rare
in polyGISTs (2/9), and 38% of them were telomeric
(biGISTs mean CS losses 3.23, range [0 to 9]; poly-
GISTs mean CS losses 1.33, range [0 to 10]); however
the difference was not significant (P = 0.2).
Copy neutral loss of heterozygosity
Copy-neutral loss of heterozygosity (cnLOH ) was frequent
in our samples. Three types of cnLOH were observed in-
volving whole chromosomes, chromosome arms and/or
chromosome segments. Whole C and CA cnLOH were de-
tected in 16/22 (73%) tumors (7/9 polyGISTs and 9/13
biGISTs) (Figure 2, Table 1, Additional file 2: Table S1).
The most frequently involved arms were: 4q (41%), 11p
(27%), 11q (23%), 1p (18%), 2q (18%), 3p (18%) and 10
(18%). Chromosome arms 12p, 12q, 19p, 20p and 20q were
never involved in cnLOH. Gains with LOH were detected
in three polyGISTs and were associated with three and four
copies of a small number of chromosomes.
Identification of commonly altered regions
All genotyping data (copy number alterations and allele
disequilibrium) were examined and combined to identify
the most frequently altered common overlapping regions.
Sixty-nine common overlapping regions were identified
(Additional file 3: Table S2): each was altered in more than
20% of tumors. They were between 70 kb and 6100 kb
long, and included one to 48 genes.
Homozygous deletion and amplification
Numerous bi-allelic deletions (homozygous deletions)
were detected. However, most of these bi-allelic dele-
tions were considered to not be significant: they were
Figure 2 Combination of copy number alteration (CNA) and allele disequilibrium (AD) data for the 22 GIST samples. For each tumor,
copy number abnormalities and allele disequilibria are represented in two columns by color code bars. The corrected CNA data (after FISH
verification) for tumors #1C2, #15C2 and #20 s2 are presented. The genetic deletions and gains are represented in green and red, respectively.
Two copies without LOH are represented in white, and regions of cnLOH are in yellow. The level of loss of allele disequilibrium is indicated in
grey. Each line corresponds to a mean value of 100 consecutive SNP. Non-continuous lines indicate the centromeres. Chromosomes are indicated
in the first column on the left.
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ger bi-allelic deletions of 48 regions were detected in 16
tumors and involved numerous different genes (Table 2).
Most of these bi-allelic deletions were detected only
once, but some were observed in at least two cases. For
example, CDKN2A and CDKN2B in 9p21.3 were deleted
in four different GISTs. The known cellular functions of13 deleted genes implicate them in oncogenesis (Table 2).
Three genes with bi-allelic deletion (CDKN2A, CDKN2B,
TUSC1) map in two of the most frequently altered com-
mon overlapping regions. One region on chromosome 8
was deleted in five GISTs and one on chromosome 11 in
two GISTs. They encompassed the same SNPs in all cor-
responding samples, possibly suggesting polymorphism
Table 1 Summary of mean chromosome number abnormalities in tumors and the % of GISTs harboring the
corresponding type of chromosome aberrations
GIST groups Type of chromosomeaberration
Average nb of
losses/tumor
[min-max]
% of GIST
Average nb of
gains/tumor
[min-max]
% of GIST
Average nb of
cnLOH/tumor
[min-max]
% of GIST
PolyGIST (n = 9) Whole chr. 0.44 [0–3] 22% 23 [9–43] 100% 3.67 [0–12] 55%
Chr. Arm 0 [0] 0% 3.11 [1–5] 100% 1.11 [0–3] 55%
Segmental 1.33 [0–10] 22% 10 [0–35] 100% 2.67 [0–7] 44%
BiGIST (n = 13) Whole chr. 2.23 [0–6] 92% 0.07 [0–1] 8% 0.38 [0–1] 38%
Chr. Arm 1.46 [0–5] 77% 0.85 [0–4] 54% 0.39 [0–2] 23%
Segmental 3.23 [0–9] 69% 0.77 [0–4] 38% 0.85 [0–4] 31%
All GIST (n = 22) Whole chr. 1.5 [0–6] 64% 9.45 [0–43] 45% 1.72 [0–12] 45%
Chr. Arm 0.86 [0–5] 45% 1.78 [0–5] 73% 0.86 [0–3] 36%
Segmental 2.45 [0–10] 50% 4.54 [0–35] 64% 1.59 [0–7] 36%
The minimum and maximum numbers of chromosome aberrations in tumors are indicated in the brackets. Chr – chromosome, Nb – number.
Table 2 Genes mapping in regions with significant bi-allelic
deletions and amplifications
Chromosome Genes localized in bi-allelic deleted regions
1 AGBL4 (2), AHDC1, AMY1A, AMY2A, AMY1B, AMY2B,
AMY1C, C1orf174, CEP104, DFFB, FAM76A, FGR, IFI6,
RNPC3, STX12, WASF2
2 LRP1B (3)
3 FAM86D, FRG2C, LMLN
6 AGER, AGPAT1, ATF6B, BTNL24B, CREBL1, CYP21A2,
CHCG4P6, EGFL8, FKBPL, HCG2P7, HLA-DQA1 (3),
HLA-DQA2, HLA-DQB1 (3), HLA-DQB2, HLA-DRA,
HLA-DRB1 (3), HLADRB5 (6), HLA-H, GPSM3, NOTCH4,
PBX2, PPT2, PRRT1, RAGE, RNF5, STK19, TNXB
8 ADAM5P (6), ADAM3A (6)
9 CDKN2A (4), CDKN2B (3), DMRTA1, FNBP1, MTAP,
TUSC1
10 PTEN
11 ELP4 (2)
14 BAZ1A, FAM177A1, IGBP1P1, PPP2R5E (2), PPPR2R3C,
SGPP1 (2), SRP54, WDR89 (2)
15 A26B1 (2), GOLGA8A, PWRN2
22 CRYBB2, IGLL3, LRP5L
Chromosome Genes localized in amplified regions
4 ANAPC4, CCDC149, CCKAR, LGI2, LOC389203, PCDH7,
PI4K2B, RBPJ, SEPSECS, SLC34A2, SOD3, STIM2,
TBC1D19, ZCCHC4
5 FGF10
7 ZNF680
8 ADAM3A, ADAM2
11 JRKL, CNTN5, TRIM48
19 LOC642290
The number of GISTs with the identified gene deletion is indicated in the
brackets. The number of GISTs is not indicated when the gene is deleted in
only one tumor. Genes with functions implicating them in GIST oncogenesis
are shown in bold.
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morphic region in chromosome 6 manifested frequent
deletion of genes coding for proteins of the immune sys-
tem response.
Amplification was a rare genetic event in our series of
GISTs. Only 34 amplified regions were detected, and
only nine of these were considered to be important (lon-
ger than 100 kb or containing more than 30 SNP)
(Table 2). Even in these cases, the level of amplification
was not very high (5–8 copies).
CDKN2A and CDKN2B breakpoint analysis
For the 9p chromosome region spanning CDKN2A and
CDKN2B, we confirmed with precision the location of
the allelic breakpoints. Several breakpoints were mapped
within the CDKN2A and/or CDKN2B loci (9p21), so we
quantified the number of DNA copies by quantitative
multiplex PCR of short fluorescent fragments (QMPSF)
within this region. Allelic breakpoints detected in four
patients (#3C2, #5C3, #18C3, #27s2) by SNP arrays ana-
lysis were confirmed by QMPSF (Figure 3). Four control
patients without breakpoints were studied by QMPSF:
no DNA copy number alteration was detected in the re-
gion analyzed.
Correlations of chromosomal 4 alterations with WT KIT
deletion
The KIT exon 11 mutations in the 22 patients consisted
of 14 deletions, five substitutions, two complex muta-
tions (delins) and one insertion (Table 3). Based on
length analysis of PCR products or Sanger sequences, 11
patients were initially considered as having a loss of WT
KIT: nine of these 11 patients (81%) had a cnLOH,
which involved the entire 4q in eight cases; the two
other cases had a monosomy and a gain of 4q with
LOH. The proportion of GISTs with cnLOH involving
an entire chromosome arm was higher among tumors
Figure 3 Localization of allelic breakpoints as determined from the SNP array and QMPSF in the CDKN2A/CDKN2B genes. In case #3C2, #5C3
and #18C3, the copy number varied within this locus according to SNP analysis, and was confirmed by QMPSF. For QMPSF quantification, DMRTA1 was
used as a control gene.
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ing the WT allele (27% of GISTs) (P < 0.05).
Overall and progression free survival analysis
Progression-free survival and overall survival curves were
first compared between KIT mutated/KIT WT- (n = 11)
and KIT mutated/KIT WT+ (n = 11) groups of patients,
and then between polyGISTs (n = 9) and biGISTs (n = 13).
No significant differences were observed between any of
the groups analyzed (P > 0.5) (Additional file 4: Figure S2,
Additional file 5: Figure S3).
Discussion
We performed a whole genome analysis of 22 GISTs
with SNP and CGH arrays, and detected numerous dif-
ferent chromosome alterations in most patients. Most of
these alterations affected whole chromosomes or chromo-
some arms. These alterations consisted of gains, losses
and cnLOH. We also identified the most frequently al-
tered overlapping regions that may contain genes involved
in GIST tumorigenesis. We also describe the presence of
bi-allelic deletions and rare amplifications.
Chromosome alterations in GIST have previously been
studied by classic cytogenetics [12,13,16,27], CGH arrays
[28] and SNP arrays [29]. These studies demonstrated
that gains and losses of whole C/CA are frequent events
in GISTs. Gains frequently involve chromosomes 5 and 8,
whereas most losses affect 1p, 14, 15 or 22 [12,13,15-21].
Our work with high density SNP arrays, CGH arrays and
FISH on 22 GISTs with KIT exon 11 mutations confirms
these data. Losses were detected in 14/22 (63%) tumors.
The most frequently involved chromosomes/chromosome
arms were 14 (n = 50%), 22 (n = 41%), 1p (n = 36%) and
15 (n = 27%), which is in accordance with previouslypublished data [18]. Some of these chromosomal alter-
ations have been linked to tumor location [28] and
some studies suggest that they may have prognostic
significance [16,18-20]. The tumors we studied could
be classified into two groups with numerous or few
chromosomes variations. The ‘numerous chromosome
variations’ phenotype has been described as chromo-
some instability, and may be related to mutations in a
driver gene [30]. It has been reported to be associated
with a poor prognosis, but our analysis failed to con-
firm this possibility.
An important finding of our study is the detection of
frequent cnLOH in GISTs. The phenomenon of cnLOH
was first described as uniparental disomy (UPD) [31],
and is responsible for parental imprinting in some inher-
ited conditions, such as Prader-Willi syndrome [32]. The
identification of somatic cnLOH (or “acquired UPD”) in
tumors was more recent [33]. High-density SNP arrays
are now available and can be used for analysis of both
SNP-based genotype and DNA copy number allowing the
detection of cnLOH, which was undetectable by cytogen-
etic methods. Such cnLOH is a frequent chromosomal
alteration in human hematological malignancies, such
as leukemia [34], mantle cell lymphomas [35] and follicu-
lar lymphoma [36]. For cases of hematological malig-
nancy, samples can be enriched in tumor cells by flow
cytometry, making this type of analysis suitable for these
diseases. Loss of a WT allele or cnLOH were previously
reported in GISTs with mutations in exon 9 of KIT
[29,37,38], and cnLOH was described in a few series of
breast [39], endometrial [40], and colorectal carcinomas
[41]. However, the frequency of cnLOH in solid tumors
may have been underestimated because the percentages of
tumor cells in the samples analyzed were low. By contrast,
Table 3 Clinico-pathological and genetic data for 22 GISTs
Tumor
name Sex
Age at
diagnosis
Tumor
location*
KITWT
status** KIT Mutation
Stage at
diagnosis*** Fletcher **** Histology *****
Mitotic
Index/
50HPF
Complementary
analysis
1C2 M 53 Sm WT- c.1653_1661del,
p.552-554del
L NA F >10 CGH, FISH
3C2 M 59 Ga WT- c.1653_1670del,
p.552_557del
M HR M >10 CGH
4C F 42 D WT- c.1708_1728del,
p.570-576del
R LR F 0 CGH
6C3 M 67 R WT- c.1648-5_1670del,
p.550-558del
R HR E >10 CGH
18C3 F 47 Sm WT- c.1679 T >A,
p.V560D
R NA F >10 CGH
20 s2 M 57 Ga WT- c.1666_1680del,
p.556_560del
M HR F >10 CGH, FISH
28 s2 F 57 D WT- c.1679_1681del,
p.560del
R NA F NA NR
29 s2 M 60 Ga WT- c.1669_1674del,
p.557_558del
R HR M >10 CGH
30 s2 M 85 M WT- c1669 T >A,
pW557R
L HR F >10 NR
31 s2 M 53 Sm WT- c1658-1669del,
p.553-556del
M HR F >10 NR
32 s2 F 43 Sm WT- c1670-1675Del,
p.557_559delinsF
NA NA F 2 NR
2P2 M 82 Ga WT+ c.1670_1675del,
p.557_559delinsF
M HR F >10 NR
5C3 F 64 D WT+ c.1669_1716del,
p.557-572del
R HR M NA NR
10C2 M 66 Sm WT+ c.1669_1674del,
p.557_558del
R HR F >10 NR
14C2 F 60 Ga WT+ c.1679_1681del,
p.560del
R HR F 2 NR
15C2 F 54 Sm WT+ c.1676 T >G,
p.V559G
R IR F 1 FISH
22 s2 F 54 Ga WT+ c.1679 T >G,
p.V560G
NA LR F 1 NR
23 s2 F 45 Ga WT+ c.1658_1674delinsCTGAA,
p.553-558delinsSE
NA LR F 0 NR
24 s2 F 57 D WT+ c.1673_1674insTCC,
p.558delinsNP
R LR F 0 CGH
12C2 M 39 Ga WT+ c.1700_1726delinsGTTGTG,
p.567-576SdelinSCV
R HR E 0 NR
19 s2 M 55 Ga WT+ c.1679 T >A, p.V560D R HR E >10 CGH
27 s2 M 59 Ga WT+ c.1669_1680del,
p.557-560del
R HR M >10 CGH
*Sm: small intestine; Ga: gastric; D: duodenum; M: mesenteric; R: rectum.
**WT-: loss of wild type allele of KIT; WT+: presence of the wild type allele of KIT.
***L: localy advanced; M: metastatic; R: resectable.
****According to Fletcher classification: HR: High risk; LR: low risk; IR: intermediate risk.
*****F: spindled cells; E: epithelioid form: M: mixed form.
NA – not available, NR – not realized.
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erally low, and in the present study, more than 95% of
all samples were tumor cells. Additional studies usingalgorithms adapted to low tumor percentage [42] are
needed to determine whether cnLOH is also frequent
in other human solid tumors.
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C/CA and segmental cnLOH (telomeric or interstitial).
Various mechanisms can lead to cnLOH and are prob-
ably different for these two types [43]. Whole C/CA
cnLOH may result from the loss of a chromosome/
chromosome arm followed by chromosomal duplication
of the paired chromosome/chromosome arm, or from a
non-disjunction event during mitosis followed by loss of
the supernumerary chromosome/chromosome arm. Seg-
mental cnLOH can be secondary to a homologous som-
atic recombination: this seems to be the major mechanism
responsible for cnLOH in hematological malignancies [44]
but still not well understood; it may be a cellular attempt
to correct a deletion or repair double-strand breaks in the
DNA. We show here that in GISTs, most cnLOH were
whole C/CA type. Furthermore, all biGISTs with cnLOH
also had losses of chromosome arms. The cnLOH in
GISTs may be due to a loss of chromosome material dur-
ing mitosis followed by duplication of the paired material.
This hypothesis is controversial, and other studies have
described cnLOH in GISTs as being mostly segmental,
suggesting mitotic recombination as the major mechan-
ism of cnLOH [45]. Different inclusion criteria of tumors
samples as well as different normalization and data-
mining methods used in this study and in previously pub-
lished data may in part cause these disparate observations.
The pathogenic consequences of cnLOH in cancer
are multiple; it may give rise to homozygosity for a
mutated tumor suppressor gene promoting tumor growth
or chemotherapy resistance. Homozygosity may also
change the methylation equilibrium of regulatory re-
gions and result in epigenetic modulation of oncogenic
pathways. Recently, cnLOH was observed in approxi-
mately 40% of patients with relapsed acute myeloid
leukemia [44] suggesting that it may be a mechanism
for cancer progression in many cases. It has been re-
ported that cnLOH is associated with JAK2 or FLT3 in-
ternal tandem duplication with oncogenic mutations in
acute myeloid leukemias [44,46] and may also contrib-
ute to inactivating tumor suppressor genes in colorec-
tal cancer, for example hMLH1 [47]. Homozygosity of
JAK2 V617F and of FLT3 mutations is associated with
a poorer prognosis of patients with leukemia or myelo-
proliferative disorders [46,48].
One of our aims was to determine the causes of the
KIT mutation “homozygosity” observed in some GISTs.
We detected cnLOH in chromosome 4q in 9/11 GISTs
with KIT WT allele loss (81% of cases), whereas only
one case showed LOH associated with 4q monosomy;
the other case had a gain of 4q with loss of the KIT WT
allele. Thus, KIT mutation homozygosity is due to cnLOH
in most GISTs. GISTs with homozygous mutations of KIT
have been reported to have a poor prognosis in a small
number of independent series [23,26], although, in ourseries, there was no correlation with survival. However,
our series was designed for molecular analyses: we specif-
ically enriched the population with GISTs with a loss of
WT KIT, and those with mutated KIT/WT KIT were se-
lected mainly to match the type of KIT exon 11 and are
thus not representative of GISTs in general. Large un-
biased series are required to correlate cnLOH, gain of 4q
and/or “homozygous” KIT mutations with clinical charac-
teristics and survival. The absence of matched blood sam-
ples may be responsible for the false positive detection of
cnLOH that coincide with inherited regions of homozy-
gosity. However, the risk of false positives is mainly associ-
ated with small segments of partial cnLOH; the risk is
therefore relatively small in our series of GISTs as almost
all the cnLOH detected were large.
In addition to chromosome instability, we detected nu-
merous genomic alterations including bi-allelic deletions
and amplifications. By using quantitative real-time PCR
for sequences in the 9p21 region, we confirmed, with
precision, the sites of the breakpoints detected with SNP
arrays. We reported significant complete deletions of 48
regions involving numerous different genes; this thus
implicates some of these genes in carcinogenesis, par-
ticularly those with functions in the cycle cell, DNA re-
pair or apoptosis. Some of these genes with bi-allelic
deletions map in common overlapping regions frequently
altered in our series (CDKN2A, CDKN2B, TUSC1), pro-
viding further arguments in favor of them having a role in
GIST oncogenesis. Deletion of CDKN2A in GISTs has
already been reported, and is associated with a poor prog-
nosis [13]. Functional studies are necessary to determine
whether the abnormalities of some of these genes may be
responsible for, rather a consequence of, the substantial
chromosomal instability of GISTs.
Conclusions
Our whole genome analysis confirms that GISTs display
chromosomal instability involving whole chromosomes
and/or chromosome arms. Two main types of chromo-
somal instability were observed: abundant gains and
cnLOH, and their occurrence was independent in this
series. There were numerous cases of cnLOH, which
was responsible for KIT exon 11 mutation homozygosity.
Several potential tumor driver genes were also detected.
Functional studies are necessary to determine whether
some of these gene anomalies are responsible for, rather
than a consequence of, the high chromosomal instability
of GISTs.
Materials and methods
Patients
KIT-positive GISTs carring mutations in exon 11 of KIT
were selected from the Ambroise Paré hospital tissue
bank database. All patients with loss of the WT KIT
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frozen or paraffin-embedded material. Eleven tumors
with heterozygous KIT exon 11 mutations were used as
controls.
All GIST patients included in this genotyping analysis
had previously participated in the MolecGIST study [5].
Participants in MolecGIST provided their verbal in-
formed consent to participate in this study after reading
an information note. MolecGIST was approved by the
appropriate French ethics committee: “Comité pour la
Protection des Personnes se prêtant à des Recherches
Biomédicales” (CPPRB, Committee for the Protection of
Persons suitable for Biomedical Research) Saint Germain
en Laye #06029, April 24th 2006.
All relevant information about the patients and tumor
samples is given in Table 3. The median age of the 22
patients was 57 years (range [39 to 85]), and there were
12 men and 10 women. GISTs were localized in stomach
(n = 10), duodenum (n = 4), small intestine (n = 6), rectum
(n = 1) and mesentery (n = 1). Most samples analyzed were
obtained from primary tumors, except for the samples from
patients #32 s2 and #2P2 (metastases), and #1C2, #18C3
(intra-abdominal relapse). One sample was obtained after
treatment with imatinib (#18C3). The types of exon 11 mu-
tations are described in Table 3. According to the Fletcher
classification estimating malignancy potential, 13 tumors
were at high risk, two at intermediate risk, and three at low
risk; for four samples the relevant information was not
available. The mitotic count was higher than 10/50 HPF for
12 samples, between 5 and 10/50 HPF for one sample and
less than 5/50 HPF for eight samples; the mitotic count
was not known for one sample.
DNA extraction
Genomic DNA was extracted from either frozen or
paraffin-embedded fragments of GIST as previously de-
scribed [22]. Histological control with hematoxylin &
eosin staining was performed on each sample before and
after cutting the slides for DNA extraction. Tissue sam-
ples were macrodissected, and at least 90% of the cells
in the samples used for DNA extraction were tumor
cells. DNA samples were analyzed with a spectropho-
tometer (ND-100, Nanodrop®) and by electrophoresis,
and only samples with a molecular weight higher than
2,5Kb were selected for SNP arrays.
Identification of KIT mutation
The method for identification of KIT mutation has been
described previously [49]. Relative amounts of WT and
mutated alleles of KIT in patients with deletions or in-
sertions were determined by analysis of fluorescent PCR
products, and loss of WT KIT was defined as a [mutated/
wild type] ratio higher than 1.5 [23]. Patients with a
single nucleotide substitution mutation were consideredas homozygous, if the WT nucleotide peak was at least
three times lower than that the mutant peak in both for-
ward and reverse Sanger sequences.
Whole genome analysis
GIST DNA samples were hybridized on Human370CNV-
QUAD SNP arrays (Infinium Ilumina®) according to the
manufacturer’s instructions by IntegraGen (Evry, France).
This array contains over 370000 probes distributed
throughout the genome with a median coverage of one
probe every 5000 bases. However, the array does not
include chromosome 13p, 14p, 15p, 21p or 22p markers.
Chromosomes Y and X were only used to verify the sex of
the patient. All genome positions were based upon
NCBI36/hg18 from UCSC Genome Bioinformatics.
The fluorescence intensity data extracted using Illumi-
na’s BeadScan software was analyzed twice by two differ-
ent methods. In the first approach, the intensity data were
normalized as described by Illumina Inc [50] with Integra-
Gen commercial platform assistance. SNP genotyping data
was plotted in Illumina Genome Viewer and Chromosome
Browser of Illumina’s BeadStudio3.0 (Illumina Inc., San
Diego, CA, USA) that chromosome aberrations were visu-
alized and identified in respect to their localization. Re-
gions with B allele Freq values and LOH Score suggestive
of LOH without the modification in Log R values were
considered as cnLOH segments. However, normalization
and data-mining of Illumina platform was originally de-
signed for genotyping of normal genomes. In the second
analysis, the genotyping data were normalized and ana-
lyzed with tQN8 and GAP methods [51,52] by the bio-
statistics platform of la Ligue contre le Cancer. tQN8
normalization strategy was showed to improve the quality
of Illumina arrays data of cancer genomes when used for
LOH and copy number variations studies [51]. GAP
method was also developed for complex cancer ge-
nomes to analyze segmental copy numbers, genotype
status and overall genomic ploidy of tumors [52]. Add-
itionally, CNA and AD were visually investigated on
BeadStudio software (version3) by two independent re-
searchers. Chromosome aberrations containing 30 SNP
or more and/or longer than 100 kb were considered as
true. Chromosome abnormalities were compared between
tumors to detect the most frequently altered common
overlapping regions (present in >20% of tumors). For tu-
mors with ploidy higher than two, gains and losses were
defined according to their ploidy level in this analysis. For
tumors with chromosome numbers near 46, 69 and 92,
the presence of more than four, five and six copies, re-
spectively, were considered to be amplifications.
IntegraChipTM (CIT-CGH Homo sapiens BAC) arrays
were hybridized with tumor DNA from 10 patients by
the IntegraGene commercial platform according to the
manufacturer’s instructions.
Lourenço et al. Molecular Cancer 2014, 13:246 Page 10 of 12
http://www.molecular-cancer.com/content/13/1/246The results for 22 of the 36 samples hybridized on SNP
arrays were of sufficient quality for analysis. Only 1 of the
13 arrays obtained with DNA extracted from paraffin-
embedded tissue was of acceptable quality, whereas 21/23
samples from frozen tissue were satisfactory. The median
call rate of the 22 samples was 98% (range [0.93 to 0.998]).
Quantitative Multiplex PCR of Short Fluorescent
Fragments (QMPSF) analysis
QMPSF is a sensitive method involving the simultaneous
amplification of short genomic fragments using dye-labeled
primers under quantitative conditions, and was used for the
detection of 9p21 genomic deletions. The assay employed
ten primer pairs that cover a 2.8 Mb region and five genes
(Telomere >MIR31/MTAP/CDKN2A/CDKN2B/DMRTA1>
Centromere) located in the 9p21 locus and generates PCR
fragments of 150 to 250 base pairs. PCR conditions for
QMPSF analyses of CDKN2A and CDKN2B loci have been
described previously [53]. Briefly, 100 ng of genomic DNA
was used in a final volume of 25 uL with 0.16 mmol/L of
each deoxynucleoside triphosphate, 1.5 mmol/L MgCl2, 1
unit of thermoprime Plus DNA polymerase (ABgene), 5%
dimethyl sulfoxide and 0.5 to 1.6 mmol/L of each primer,
one primer of each pair carrying a 6-carboxyfluorescein
label. After an initial denaturation for 3 min at 94°C, 20 cy-
cles were performed consisting of denaturation at 94°C for
15 s, annealing at 90°C for 15 s (ramping 3°C/s) and ex-
tension at 70°C for 15 s (ramping 3°C/s), followed by a
final extension step for 5 min at 70°C. PCR products were
analyzed on a sequencing platform used in the fragment
analysis mode in which both peak heights and areas are
proportional to the quantity of template present for each
target sequence.
FISH
Imprints of GISTs cells were obtained with briefly defrosted
tumor samples. For each sample, one slide was stained with
Giemsa for cytological control. Two centromere probes,
one for each chromosomes 4 and 18 (CEN4, CEN18)
(Kreatech Biotechnology) were used and six BAC probes –
RP11-93 L18, RP11-983 F2 (chr17), RP11-959 K5, RP11-
642 F17 (chr22), RP11-586A2 (chr4) and RP-11-121G9
(chr7) – were produced: bacteria carrying a BAC vector
were grown overnight on solid agar medium, and then cul-
tured overnight in LB medium. BAC DNA was extracted
using NucleoBond PC 500 or NucleoBand Xtra BAC
Kits (Macherey-Nagel) as recommended by producer.
Aliquots of 1 μg of DNA were labeled by nick-translation
according to the kit manufacturer’s instructions (Nick
Translation Kit, Abott). The labeled DNA (the probe) was
precipitated by incubation overnight at −20°C in the pres-
ence of human cot DNA, sodium acetate and ethanol,
and then resuspended in hybridization buffer (LSI/WCP
Hybridization Buffer, Abott). The probes were used at afinal concentration of 40–50 ng/μL. Commercial probes
were applied according to the manufacturer’s recommen-
dations (Kreatech Biotechnology). Co-denaturation of the
probes and the tumor section were performed to create
single-stranded DNA. Fluorescence signals were analyzed
using a Leica DM4000B microscope equipped with ap-
propriate filters and a 22 DFC300FX camera under the
control of LAS V4.0 software (Leica). The fluorescence
signals in at least 10 nuclei were counted.Statistical analysis
Survival curves were estimated using the Kaplan-Meier
method, and differences between curves were assessed
using the log-rank test. The threshold for significance
was set at a p-value of 5%. The analysis was conducted
using R software (2.14.1). Progression-free survival (PFS)
is defined as the time interval between surgery and first
evidence of disease progression or relapse. Overall sur-
vival (OS) is defined as the time interval between GIST
diagnosis and death or last news. T-tests were used as
appropriate.Additional files
Additional file 1: Figure S1. CGH array karyotyping data for 10 GISTs.
Chromosome copy number state: deletions (green), gains (red), two
copies (white). Chromosomes are indicated in the first column on the left.
Additional file 2: Table S1. Cytogenetic findings and cnLOH data
detected for 22 GISTs.
Additional file 3: Table S2. Identification of common genetic alterations
in 22 GISTs: chromosome aberrations longer than 100 kb and/or containing
30 SNP or more were included. Regions of chromosome loss and gain are
represented by chromosome numbers on green and red backgrounds,
respectively.
Additional file 4: Figure S2. Overall survival (OS) curves for patients
with GISTs. A) Overall survival curves according to polyploidy level. No
significant difference in OS was detected between polyGIST and biGIST
groups. B) Overall survival curves according to KIT exon 11 mutation
status. No significant difference in OS was detected between homozygous
and heterozygous exon 11 mutated groups. WT + = WT allele present,
WT- = WT allele loss.
Additional file 5: Figure S3. Progression-free survival (PFS) curves for
patients with GISTs. A) Progression-free survival curves according to polyploidy
level. There was no significant difference in PFS was observed between
polyGISTs and biGISTs groups. B) PFS curves according to KIT exon 11
mutation status. There was no significant difference in PFS between
homozygous and heterozygous exon 11 mutated groups. WT + = WT
allele present, WT- = WT allele loss.Competing interests
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